HealthQuill
The UK Health Security Agency and the Met Office have issued an amber heat-health alert for all regions of England for the next four days.
Climate Health Medical

UK health agency, Met Office, issues an amber alert as temperatures rise

HQ Team June 19, 2025: The UK Health Security Agency and the Met Office have issued an amber heat-health alert for all regions.

Read More
Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from the US regulator.
Uncategorized

Gilead’s Yeztugo drug for HIV prevention in adults gets FDA nod

HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.

Read More
Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.
Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

Read More
The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’ living cells to China and other “hostile countries” for the fear of genetic data misuse.
Drugs Health Pharma

US to review trials to stop genetic data misuse by China, ‘hostile’ nations

HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.

Read More
Men haunted by a Yakshi are not victims of a supernatural encounter. They are confronting disowned parts of themselves. The Yakshi’s irresistible beauty reflects their desire, while her terrifying, bloodthirsty violence symbolises their guilt and fear of unacceptable desires. 
Health Medical Opinion

Treat ghosts who lure men to their demise as a guide, and not a villain

By Aparna S June 19, 2025: In the 1990s, no vacation was considered complete without the obligatory ghost story session. Every cousin, uncle,.

Read More
The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between 18 and 59 years.
Drugs Health Pharma

US regulator gives nod for Moderna’s expanded use of mRNA vaccine

HQ Team June 13, 2025: The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between.

Read More
Rein Therapeutics, Inc. has paused its enrollment and patient dosing at its US clinical trial sites testing a lung disease drug, after the regulator placed the experiment on clinical hold. 
Drugs Health Pharma

Rein Therapeutics’ trial drug for lung disease disorder put on clinical hold

HQ Team July 13, 2025: Rein Therapeutics, Inc., has paused its enrollment and patient dosing at its US clinical trial sites testing a.

Read More
UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been approved by the US Food and Drug Administration.
Drugs Health Pharma

FDA approves UroGen’s muscle-invasive bladder cancer therapy

HQ Team June 13, 2025: UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been.

Read More
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More
Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.
Drugs Health Pharma

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

Read More